PureTech Health plc Stock
Stocks
PRTC
GB00BY2Z0H74
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Cboe Europe
12:23:28 28/08/2026 +04
|
5-day change | 1st Jan Change | ||
| 127.70 GBX | +1.35% |
|
+7.38% | +2.40% |
| 07-13 | PureTech Health announces first patient dosing in Celea phase 3 trial | AN |
| 07-13 | PureTech Health: Celea Therapeutics Kicks Off Late-stage Trial for Idiopathic Pulmonary Fibrosis Drug | MT |
| Market Cap | 417M 358M 335M 307M 578M 39.81B 579M 3.97B 1.55B 20.06B 1.56B 1.53B 66.4B | P/E 2026 * |
-3.75x | P/E 2027 * | -4.48x |
|---|---|---|---|---|---|
| Enterprise Value | 148M 127M 119M 109M 205M 14.12B 206M 1.41B 550M 7.12B 555M 543M 23.55B | EV / Sales 2026 * |
20.8x | EV / Sales 2027 * | 12.8x |
| Free-Float |
84.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : PureTech Health plc
| 1 day | +1.35% | ||
| 1 week | +7.38% | ||
| Current month | +7.56% | ||
| 1 month | +4.92% | ||
| 3 months | -8.70% | ||
| 6 months | +4.23% | ||
| Current year | +2.40% |
| 1 week | 114 |  | 128 |
| 1 month | 113 | | 128 |
| Current year | 107.4 | | 143.6 |
| 1 year | 104.71 | | 143.6 |
| 3 years | 100.4 | | 238.5 |
| 5 years | 100.4 | | 410.66 |
| 10 years | 100.4 | | 447.66 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Lyne
CEO | Chief Executive Officer | 43 | 15/07/2025 |
Eric Elenko
PSD | President | 53 | 09/04/2024 |
Charles Sherwood
COO | Chief Operating Officer | - | 01/08/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Langer
BRD | Director/Board Member | 76 | 08/05/2015 |
John LaMattina
BRD | Director/Board Member | 76 | 01/01/2009 |
| Director/Board Member | 73 | 01/10/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 24/09/25 | Buy | Chief Executive Officer | 81,051 | 0.0337% | ||
| 24/09/25 | Buy | Director | 29,239 | 0.0122% | ||
| 24/09/25 | Buy | Chairman | 65,250 | 0.0272% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.35% | +7.38% | -4.48% | -33.68% | 417M | |
| -0.32% | -1.01% | +2.91% | +23.28% | 51.14B | |
| +2.65% | +4.45% | +481.36% | +567.32% | 47.4B | |
| +0.33% | +2.47% | +38.97% | +19.80% | 43.19B | |
| -0.88% | +0.90% | +24.11% | +87.74% | 42.35B | |
| -2.27% | -3.02% | +14.22% | +51.50% | 33.23B | |
| -1.21% | -0.17% | +29.16% | +135.38% | 17.07B | |
| -0.36% | -2.14% | - | - | 16.38B | |
| -0.30% | -0.08% | +12.25% | +28.50% | 14.76B | |
| +0.44% | +1.70% | +82.07% | +47.92% | 14.15B | |
| Average | -0.06% | +1.35% | +75.62% | +103.08% | 28.01B | |
| Weighted average by Cap. | -0.05% | +1.05% | +106.10% | +143.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.1M 6.09M 5.71M 5.22M 9.84M 678M 9.87M 67.57M 26.41M 342M 26.66M 26.08M 1.13B | 13.47M 11.56M 10.82M 9.91M 18.67M 1.29B 18.72M 128M 50.1M 648M 50.56M 49.47M 2.15B |
| Net income | -124M -107M -99.73M -91.32M -172M -11.85B -173M -1.18B -462M -5.97B -466M -456M -19.77B | -96.8M -83.09M -77.79M -71.23M -134M -9.25B -135M -921M -360M -4.66B -363M -356M -15.42B |
| Net Debt | -269M -231M -216M -198M -373M -25.69B -374M -2.56B -1B -12.95B -1.01B -988M -42.84B | -244M -210M -196M -180M -339M -23.34B -340M -2.33B -909M -11.76B -917M -898M -38.93B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | GBX 128.00 | +1.59% | 210,765 |
| 27/08/26 | GBX 126.00 | +4.65% | 1,560,101 |
| 26/08/26 | GBX 120.40 | -0.66% | 2,780,081 |
| 25/08/26 | GBX 121.20 | +2.02% | 1,301,758 |
| 24/08/26 | GBX 118.80 | +1.02% | 1,172,728 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PRTC Stock
Select your edition
All financial news and data tailored to specific country editions
